Market Overview

Argus: Anthrax Vaccine Maker Emergent BioSolutions Poised For Earnings Growth

Argus: Anthrax Vaccine Maker Emergent BioSolutions Poised For Earnings Growth
Related EBS
The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO
The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings

Emergent Biosolutions Inc (NYSE: EBS), a maker of vaccines and products for infectious diseases as well as chemical, biological or nuclear attacks, picked up a sell-side bull Wednesday. 

The Analyst

Argus analyst Mike Jaffe initiated coverage of Emergent BioSolutions with a Buy and $62 price target.

The Thesis

With the only FDA-approved anthrax vaccine, BioThraxEmergent BioSolutions is on track to report solid earnings growth over the next several years, particularly due to strong demand from the U.S. military, Jaffe said in the initiation note. 

Argus projects that Emergent BioSolutions will benefit from recently acquired products such as the ACAM2000 for smallpox, as well as from its new product pipeline and strong cost controls.

The company, which is heavily reliant on the government for much of its revenue, has begun to diversify by developing new products for both government as well as non-government customers and through international expansion, Jaffe said. 

The discounted valuation at which the company's shares trade is warranted, given its overreliance on the U.S. government, the analyst said. That said, the current discount is too deep given expectations for 24-percent earnings growth over the next five years versus 15-percent growth among peers, according to Argus.

The Price Action

Emergent BioSolutions shares have added about 16 percent year-to-date.

At the time of publication, the stock was rallying 1.47 percent to $54.53. 

Related Links:

4 Biotech Stocks To Better Your Financial Health This Winter

Benzinga's Daily Biotech Pulse: vTv Swoons On Failed Alzheimer's Trial, Regenxbio Gets FDA Fast Track For RGX-111

Latest Ratings for EBS

Nov 2018Cantor FitzgeraldMaintainsOverweightOverweight
Nov 2018Goldman SachsUpgradesNeutralBuy
Sep 2018Chardan CapitalMaintainsBuyBuy

View More Analyst Ratings for EBS
View the Latest Analyst Ratings

Posted-In: Argus Mike JaffeAnalyst Color Price Target Initiation Analyst Ratings Best of Benzinga


Related Articles (EBS)

View Comments and Join the Discussion!

Latest Ratings

ADIMorgan StanleyDowngrades0.0
ALKSGoldman SachsDowngrades26.0
BHGECredit SuisseUpgrades25.0
BLMNMorgan StanleyUpgrades0.0
OKTADA DavidsonInitiates Coverage On62.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

KeyBanc Downgrades KMG Chemicals On Valuation, Says 'The Future Is Not Without Some Uncertainty'

Hershey Faces 'Big Challenges' Ahead, Credit Suisse Says In Downgrade